Comparison of Real-World Treatment Patterns among Psoriasis Patients Prescribed Ixekizumab or Secukinumab.
Real-world data on treatment patterns associated with use of IL-17A inhibitors in psoriasis are lacking. To compare treatment patterns between ixekizumab or secukinumab users in clinical practice. Psoriasis patients ≥18 years old with ixekizumab or secukinumab between March 1, 2016, and May 31, 2018 in IBM MarketScan® databases. Inverse probability of treatment weighting and multivariable models were used to address cohort imbalances and estimate the risks of non-persistence (60-day gap), discontinuation (≥90-day gap), switching, and the odds of adherence. 645 ixekizumab and 1,152 secukinumab users were followed for 13.7 and 16.3 months, respectively. Ixekizumab users showed higher persistence rate (54.8% vs. 45.1%, P<0.001) and lower discontinuation rate (37.8% vs. 47.5%, P<0.001) than SEC. After multivariable adjustment, Ixekizumab users had lower risks of non-persistence (HR 0.82, 95%CI 0.71-0.95) and discontinuation (HR 0.82, 95%CI 0.70-0.96), and higher odds of high adherence to treatment measured by medication possession ratio≥80% (HR 1.31, 95%CI 1.07-1.60). The risk of switching was similar between cohorts. Disease severity and clinical outcomes were unavailable. Ixekizumab users demonstrated longer drug persistence, lower discontinuation rate and risk of discontinuation, higher likelihood of adherence, and similar risk of switching compared to secukinumab users in clinical practices.